Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

40 results about "Peptostreptococcus" patented technology

Peptostreptococcus is a genus of anaerobic, Gram-positive, non-spore forming bacteria. The cells are small, spherical, and can occur in short chains, in pairs or individually. They typically move using cilia. Peptostreptococcus are slow-growing bacteria with increasing resistance to antimicrobial drugs. Peptostreptococcus is a normal inhabitant of the healthy lower reproductive tract of women.

Probiotic recolonisation therapy

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
Owner:FINCH THERAPEUTICS HLDG LLC

Probiotic recolonisation therapy

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
Owner:FINCH THERAPEUTICS HLDG LLC

Medicament combination preparation of medicinal compound containing cy-ethyl razepam

The invention relates to medicament combination preparation of medicinal compound taking cy-ethyl razepam medicinal compound containing cy-ethyl razepam or stereoisomer, pro-medicinal, medicinal salt, complex salt or / and salvation as effective constituent. The medicament combination preparation adopts the technical scheme that the cy-ethyl razepam medicinal compound, which has a general formula (1) structure and contains the cy-ethyl razepam or the stereoisomer, the pro-medicinal, the medicinal salt, the complex salt and the solvation, is taken as the effective constituent and forms the medicament combination preparation with a medicament carrier capable of being received on the pharmacy; and the preparation formulation is any preparation formulation said on the pharmacy. The invention also discloses an application of the medicament combination preparation in the process of treating the infection of bacteria taken as gram-positive bacteria like staphylococcus, pneumococcus, enterococcus faecalis, streptococcus, streptococcus bovis, streptococcus pneumoniae, peptostreptococcus, festering streptococcus pneumoniae, festering streptococcus pneumoniae, streptococcus pyogenes, streptococcus agalactiae, viridans streptococci, streptococcus bovis, streptococcus agalactiae B, group green streptococcus, corynebacterium diphtheriae and other bacteria.
Owner:LIAONING LIFENG SCI & TECH DEV

Application of lactobacillus paracasei L9 to prevention or treatment oral disease and regulation of oral cavity flora

The invention discloses an application of lactobacillus paracasei L9 to prevention or treatment oral disease and regulation of oral cavity flora. L9 can be used for preparing a medical composition anda food for preventing or treating dental caries. Research proves that L9 can notably relieve generation degree of occlusal surface E-level dental caries, after the LP is taken, the structure of the oral cavity flora is changed notably, particularly actinobacteria is notably increased, the actinobacteria of L9 group is obviously reduced, klebsiella, aerococcus, Gemella, corynebacterium and pseudomonas aeruginosa on the classification level are notably reduced, and the oral disease risk is reduced. When L9 is taken, the saliva species richness is notably reduced, the relative abundance of oraldisease relevant fungi of streptococcus salivarius, actinomycetaceae, peptostreptococcus and the like is notably reduced, and the L9 can have relieving effects on periodonitis diseases. The dental plaque flora species diversity is notably reduced, the relative abundance of leptothrix, fusobacteriaceaeand flavobacterium is notably reduced, and the L9 can have relieving effects on oral diseases of periodontal disease, halitosis, dental caries and the like.
Owner:BEIJING TECHNOLOGY AND BUSINESS UNIVERSITY

Pharmaceutical composition and food for preventing or treating oral diseases

The invention discloses a pharmaceutical composition and food for preventing or treating oral diseases. Both the composition and food comprise lactobacillus paracasei L9 and staphylococcus salivariusLD11. Studies show that the L9 and the LD11 can significantly alleviate the occurrence degree of E-level dental caries of an occlusal surface, after the composition and food containing the L9 and LD11are taken, the structures of oral floras change significantly, especially actinomycetes are significantly increased, and klebsiella, aerococcus, Gemella, corynebacterium and pseudomonas aeruginosa are significantly reduced in the category classification level. Taking of the L9 and LD11 can significantly reduce saliva species richness, the relative abundances of bacteria related to the oral diseases such as staphylococcus salivarius, actinomycetaceae and peptostreptococcus are significantly reduced, and periodontitis diseases may be alleviated; the species diversity of a dental plaque flora issignificantly reduced, the relative abundances of leptotrichia, fusobacterium and flavobacterium are all significantly reduced, and the oral diseases such as periodontal diseases, ozostomia and dental caries may be alleviated.
Owner:BEIJING TECHNOLOGY AND BUSINESS UNIVERSITY

Sustained-release injection containing antibiotic lincomycin and application thereof

The invention provides a sustained-release injection or sustained-release implant containing lincomycin antibiotic. The sustained-release injection comprises sustained-release microspheres and solvent. The microspheres contain sustained-release adjuvants and antibiotics, and the solvent is a special solvent containing suspending agent such as sodium carboxymethylcellulose and having viscosity of 100-3000cp (20-30 DEG C); and the sustained-release adjuvants are selected from poly(ethylene-co-vinylacetate) (EVAc), polifeprosan, poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), sebacic acid copolymer, albumin glue and gelatin. The sustained-release implant is made from microspheres or by other methods. The sustained-release implant or injection can be locally placed or injected into foci to locally sustained-release of drug for more than 10 days, so as to obtain and maintain local drug effective concentration while remarkably reduce the systemic toxicity of the drug. The sustained-release injection has distinct and unique therapeutic effect on local infection diseases caused by Staphylococci, Streptococci, Peptostreptococcus, Propionibacterium acnes, Enterobacter, Mycobacterium tuberculosis, Gonococcus or Meningococcus, such as chronic osteomyelitis, severe decubital ulcer, refractory skin ulcer, diabetic foot, femoral head necrosis, abscess, etc.
Owner:JINAN SHUAIHUA PHARMA TECH

Novel immunochromatography test paper for detecting human brucellosis antibody and preparing method thereof

The invention relates to the field of zoonosis immunologic diagnosis and discloses a brucellosis antibody test strip and a preparing method thereof. The brucellosis antibody test strip is prepared in a way that colloidal gold with a grain diameter of 30nm is first prepared, used as an indication mark for marking and reconstructing large peptostreptococcus proteins L, dissolved in a gold mark work solution and sprayed on glass fibers to make a gold mark pad; VirB5 genes are cloned from a brucella genome and connected to pET-28a to form an expression vector; the expression vector is converted into escherichia coli, VirB5 proteins are expressed and coat on a nitrocellulose membrane after separation and purification as a detection line, IgGs (Immunoglobulin G) bonded with the proteins L are coated on the nitrocellulose membrane as a quality control line, and an immunochromatography detection device is made. The brucella immunochromatography device has the characteristics of strong specificity, high sensitivity, great stability, simplicity, economy, rapidness and the like and has extremely significant actual application value in the monitoring and epidemic control of zoonosis.
Owner:SHIHEZI UNIVERSITY

Sustained-release agent containing mezlocillin and uses thereof

The invention discloses a sustained release injection containing mezlocillin, which consists of sustained release microspheres and menstruum, wherein, the sustained release microspheres contain sustained release excipient and penicillin antibiotics, the menstruum is special menstruum containing suspending agents such as sodium carboxymethyl cellulose and so on, and the viscosity is between 100 and 3000cp (at the temperature of between 20 and 30 DEG C); the sustained release excipient is selected from EVAc, polifeprosan, PLA, PLGA, decanedioic acid copolymers, albumin glue, gelatin and so on; and the sustained release microspheres can also be prepared into sustained release implant. The sustained release implant and the sustained release injection are locally placed or injected on a bacteria focus, which can slowly release medicine at a local lesion for 5 to 30 days and apparently decrease the systemic toxicity of the medicine when the effective medicine concentration of the local lesion is effectively obtained and maintained. The sustained release injection has a remarkable and unique treatment effect on infections caused by staphylococcus, streptococcus, peptostreptococcus, acne propionate bacillus, enterobacter, tubercle bacillus, gonococcus or meningococcus and so on, particularly on local lesions such as chronic osteomyelitis, severe bedsore, refractory skin ulcer, diabetic foot and femoral head necrosis of diabetes, and various abscesses and so on.
Owner:SHANDONG LANJIN PHARMA +1

Colorectal cancer biomarker as well as screening method and application thereof

The invention relates to a colorectal cancer biomarker as well as a screening method and application thereof, and belongs to the technical field of cancer diagnosis. The colorectal cancer biomarker provided by the invention comprises human intestinal microorganisms and / or fecal human target genes; the intestinal microorganisms of the human body comprise one or more than two of Brawtella, Pseudomonas 9, Fecal bacillus, fusiform, Wehonor coccus, Escherichia coli-Shigella, Mycobacterium, Fusobacterium, Porphyrinium, peptostreptococcus and Bacteroides; the fecal human body target spot gene comprises ADHFE1 and / or SDC2. The biomarker combination disclosed by the invention is high in sensitivity and good in specificity, and has a profound prospect for estimating the risk of colorectal cancer. According to the invention, a data model is established through the biomarker, and the model can be used for evaluating the risk of colorectal cancer.
Owner:广西爱生生命科技有限公司

Sludge decrement method by combining microwaves, biological enzyme and microorganisms

ActiveCN108439744ASolve efficiency problemsSolve the investment costSludge treatmentSpecific water treatment objectivesPeptostreptococcusMethanosarcina barkeri
The invention provides a sludge decrement method by combining microwaves, biological enzyme and microorganisms. The method comprises the steps that sludge of which the content of an organic medium is45% or above is pretreated for 15-35 min in a microwave pretreatment tank; the mixing mass ratio of lysozyme to the sludge after microwave pretreatment is 1:1,500, and a mixed solution of lysozyme andthe sludge is obtained in a reaction tank; after the mixed solution of lysozyme and the sludge is mixed with composite bacterial strains, the organic medium in the sludge is decomposed, available energy is generated, the sludge amount is decreased, and the composite bacterial strains are peptostreptococcus, veillonella, propionibacteria, fire source methanococcus lactobacillus, methanosarcina barkeri, extreme thermophilic archaea and anaerobic ammonium oxidation bacteria. According to the sludge decrement method, the microwaves, special-effect enzyme and microorganisms are adopted for completely decreasing the amount of organic medium sludge generated by a biochemical system, and the sludge is converted into the available energy through a technology; the method has the ideal decrement effect on biochemical sludge generated in the process of treating municipal wastewater and industrial wastewater.
Owner:北京赛富威环境工程技术有限公司

Sustained-release injection containing antibiotic and application thereof

The invention provides a sustained-release injection or sustained-release implant containing antibacterial drugs. The sustained-release injection comprises sustained-release microspheres and solvent. The microspheres contain sustained-release adjuvants and antibiotics, and the solvent is a special solvent containing suspending agent such as sodium carboxymethylcellulose and having viscosity of 100-3000cp (20-30 DEG C); and the sustained-release adjuvants are selected from EVAc, polifeprosan, poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), sebacic acid copolymer, albumin glue and gelatin. The sustained-release implant is made from microspheres or by other methods. The sustained-release implant or injection can be locally placed or injected into foci to locally sustained-release of drug for more than 10 days, so as to obtain and maintain local drug effective concentration while remarkably reduce the systemic toxicity of the drug. The sustained-release injection has distinct and unique therapeutic effect on local infection diseases caused by Staphylococci, Streptococci, Peptostreptococcus, Propionibacterium acnes, Enterobacter, Mycobacterium tuberculosis, Gonococcus or Meningococcus, such as chronic osteomyelitis, severe decubital ulcer, refractory skin ulcer, diabetic foot, femoral head necrosis, abscess, etc.
Owner:JINAN SHUAIHUA PHARMA TECH

Sustained-release injection containing antibiotic

The invention provides a sustained-release injection or sustained-release implant containing antibiotics. The sustained-release injection comprises sustained-release microspheres and solvent. The microspheres contain sustained-release adjuvants and antibiotics, and the solvent is a special solvent containing suspending agent such as sodium carboxymethylcellulose and having viscosity of 100-3000cp (20-30 DEG C); and the sustained-release adjuvants are selected from poly(ethylene-co-vinylacetate) (EVAc), polifeprosan, poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), sebacic acid copolymer, albumin glue and gelatin. The sustained-release implant is made from microspheres or by other methods. The sustained-release implant or injection can be locally placed or injected into foci to locally sustained-release the drug for more than 10 days, so as to obtain and maintain local drug effective concentration while remarkably reduce the systemic toxicity of the drug. The sustained-release injection has distinct and unique therapeutic effect on local infection diseases caused by Staphylococci, Streptococci, Peptostreptococcus, Propionibacterium acnes, Enterobacter, Mycobacterium tuberculosis, Gonococcus or Meningococcus, such as chronic osteomyelitis, severe decubital ulcer, refractory skin ulcer, diabetic foot, femoral head necrosis and abscess.
Owner:JINAN SHUAIHUA PHARMA TECH

Sustained-release injection containing antibiotic doxycycline and uses thereof

The invention relates to a slow-release formulation containing vibramycin as antibiotic, which is slow-released injection or slow-released implant; the injection is composed of a slow-released microsphere and dissolvent; the slow-released microsphere contains slow-released adjuvant and the antibiotic; the dissolvent is a special dissolvent containing suspending agent such as sodium carboxymethylcellulose, etc. and the viscosity of the dissolvent is 100cp-3000cp (at the temperature of 20 DEG C-30 DEC C); the slow-released adjuvant is selected from EVAc, polifeprosan, PLA, PLGA, sebacic acid copolymer, albumen glue, gelatin, etc.; the slow-released implant is prepared with the slow-released microsphere or by other methods. The slow-release formulation can be partially placed or injected in a bacterial focus to release medicine on a partial disease focus for more than 10 days slowly; valid medicine concentration on the partial focus is obtained and maintained effectively, at the same time toxicity of an entire body is remarkably reduced. The slow-release formulation containing the vibramycin as the antibiotic has remarkable and special treatment effect on infection caused by staphylococcus, streptococcus, peptostreptococcus, propionibacterium acnes, enterobacter, tubercle bacillus, gonococci and meningococcus, etc., and particularly the partial focus such as chronic osteomyelitis, severe bedsore, refractory skin ulcer, diabetic foot, femoral head necrosis and various abscesses, etc.
Owner:JINAN SHUAIHUA PHARMA TECH

Sustained-release agent containing antibiotic and uses thereof

A sustained release injection containing penicillins antibiotic consists of sustained release microsphere and dissolvant, wherein the sustained release microsphere contains sustained release auxiliary materials and penicillins antibiotic; the dissolvant is special dissolvant containing suspending agents such as sodium carboxymethyl cellulose, and the viscosity of the dissolvant is 100 to 3,000 cp (at a temperature of between 20 and 20 DEG C); the sustained release auxiliary materials are selected from EVAc, Polifeprosan, PLA, PLGA, sebacic acid copolymer, albumin glue and gelatin, etc.; the sustained release microsphere can also be made into a sustained release implantation agent. The sustained release implantation agent and sustained release injection can be partly placed or injected into a bacteria focus so as to slowly release medicine over local bacteria focus for 5 to more than 30 days, thereby obviously reducing whole-length toxicity while effectively obtaining and maintaining the effective drug concentration of local focus. The sustained release preparation has remarkable and unique therapeutic effects in curing infections caused by staphylococcus, streptococcus, peptostreptococcus, propionibacterium acnes, enterobacter, tubercle bacillus, gonococcus or meningococcus, etc., and local focuses in particular such as chronic osteomyelitis, severe bedsore, intractable skin ulcer, diabetic foot, femoral head necrosis and various abscesses.
Owner:SHANDONG LANJIN PHARMA +1

Sustained-release injection containing antibiotic sarafloxacin and uses thereof

The invention relates to a slow-release formulation containing sarafloxacin as antibiotic, which is slow-released injection or slow-released implant; the injection is composed of a slow-released microsphere and dissolvent; the slow-released microsphere contains a slow-released adjuvant and the antibiotic; the dissolvent is a special dissolvent containing suspending agent such as sodium carboxymethylcellulose, etc. and the viscosity of the dissolvent is 100cp-3000cp (at the temperature of 20 DEG C-30 DEC C); the slow-released adjuvant is selected from EVAc, polifeprosan, PLA, PLGA, sebacic acid copolymer, albumen glue, gelatin, etc.; the slow-released implant is prepared with the slow-released microsphere or by other methods. The slow-released implant can be partially placed or injected in a bacterial focus to release medicine on a partial disease focus for more than 10 days slowly; valid medicine concentration on the partial focus is obtained and maintained effectively, at the same time toxicity of an entire body is remarkably reduced. The slow-release formulation containing the sarafloxacin as the antibiotic has remarkable and special treatment effect on infection caused by staphylococcus, streptococcus, peptostreptococcus, propionibacterium acnes, enterobacter, tubercle bacillus, gonococci and meningococcus, etc., and particularly the partial focus such as chronic osteomyelitis, severe bedsore, refractory skin ulcer, diabetic foot, femoral head necrosis and various abscesses, etc..
Owner:JINAN SHUAIHUA PHARMA TECH

Sustained-release injection containing kanamycin

The invention relates to a slow-released injection comprising kanamycin, which comprises a slow-released microsphere and a dissolvent; the slow-released microsphere comprises a slow-release adjuvant and the aminoglycoside antibiotic; the dissolvent is the special dissolvent which comprises a suspending agent such as sodium carboxymethylcellulose, etc., and the viscosity of which is 100cp-3000cp (at 20 DEG C-30 DEC C); the slow-release adjuvant can be selected from EVAc, polifeprosan, PLA, PLGA, sebacic acid copolymer, albumen glue and gelatin, etc.; the slow-released microsphere also can be made into a slow-released implant and an ointment. The slow-released implant and the slow-released injection can be partially placed or injected in a bacterial focus to release locally and slowly for more than 5-30 days, thereby obviously reducing the toxicity of the entire body while getting and maintaining a valid medicine density in the local focus effectively. The slow-released injection comprising the kanamycin of the invention has obvious special treatment effect for focus of local infection such as chronic osteomyelitis, severe bedsore, refractory skin ulcer, diabetic foot, osteonecrosis of femoral head and various abscesses, etc., caused by staphylococcus, streptococcus, peptostreptococcus, propionibacterium acnes, enterobacter, tubercle bacillus, gonococcus and meningococcus, etc.
Owner:JINAN SHUAIHUA PHARMA TECH

Application of microorganism-derived plasmalogen to treatment of colon cancer

The invention discloses application of microorganism-derived plasmalogen to treatment of colon cancer, and belongs to the technical field of biological medicines and microorganisms, and aims to provide a method for improving the colon cancer. The invention provides application of microorganism-derived plasmalogen to preparation of a drug for treating colon cancer. The microorganism-derived plasmalogen is extracted from any one or more of anaerobic microbes such as lactobacillaceae, bifidobacterium, clostridium butyricum and peptostreptococcus kluyver and van niel in a mixed manner. The microorganism-derived plasmalogen can reduce the expression of colon cancer related cytokines from a molecular level, and inhibit proliferation of colon cancer cells and reduce the number and volume of colonic adenomas of a colon cancer patient, can be used as an effective nutrition strategy for preventing and treating the colon cancer, and provides a theoretical support for efficient utilization of the enteric microorganism-derived plasmalogen.
Owner:JIANGNAN UNIV

Sustained-release injection containing antibiotic danofloxain and uses thereof

The invention relates to a slow-release formulation containing danofloxacin as antibiotic, which is slow-released injection or slow-released implant; the injection is composed of a slow-released microsphere and dissolvent; the slow-released microsphere contains slow-released adjuvant and the antibiotic; the dissolvent is a special dissolvent containing suspending agent such as the sodium carboxymethylcellulose, etc. and the viscosity of the dissolvent is 100cp-3000cp (at the temperature of 20 DEG C-30 DEC C); the slow-released adjuvant is selected from EVAc, polifeprosan, PLA, PLGA, sebacic acid copolymer, albumen glue, gelatin, etc.; the slow-released implant is prepared with the slow-released microsphere or by other methods. The slow-release formulation can be partially placed or injected in a bacterial focus to release medicine on a partial disease focus for more than 10 days slowly; valid medicine concentration on the partial focus is obtained and maintained effectively, at the same time toxicity on an entire body is reduced remarkably. The slow-release formulation containing the danofloxacin as the antibiotic has a remarkable and special treatment effect on infection caused by staphylococcus, streptococcus, peptostreptococcus, propionibacterium acnes, enterobacter, tubercle bacillus, gonococci and meningococcus, etc., and particularly the partial focus such as chronic osteomyelitis, severe bedsore, refractory skin ulcer, diabetic foot, femoral head necrosis and various abscesses, etc.
Owner:JINAN SHUAIHUA PHARMA TECH

Sustained-release injection containing antibiotic and application thereof

The invention provides a sustained-release injection or sustained-release implant containing tylosin antibiotic. The sustained-release injection comprises sustained-release microspheres and solvent. The microspheres contain sustained-release adjuvants and antibiotics, and the solvent is a special solvent containing suspending agent such as sodium carboxymethylcellulose and having viscosity of 100-3000cp (20-30 DEG C); and the sustained-release adjuvants are selected from poly(ethylene-co-vinylacetate) (EVAc), polifeprosan, poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), sebacic acid copolymer, albumin glue and gelatin. The sustained-release implant is made from microspheres or by other methods. The sustained-release implant or injection can be locally placed or injected into foci to locally sustained-release of drug for more than 10 days, so as to obtain and maintain local drug effective concentration while remarkably reduce the systemic toxicity of the drug. The sustained-release injection has distinct and unique therapeutic effect on local infection diseases caused by Staphylococci, Streptococci, Peptostreptococcus, Propionibacterium acnes, Enterobacter, Mycobacterium tuberculosis, Gonococcus or Meningococcus, such as chronic osteomyelitis, severe decubital ulcer, refractory skin ulcer, diabetic foot, femoral head necrosis, abscess, etc.
Owner:JINAN SHUAIHUA PHARMA TECH

Sustained-release agent containing TIC and use thereof

A sustained release preparation containing ticarcillin consists of sustained release microsphere and dissolvant, wherein the sustained release microsphere contains sustained release auxiliary materials and penicillins antibiotic; the dissolvant is special dissolvant containing suspending agents such as sodium carboxymethyl cellulose, and the viscosity of the dissolvant is 100 to 3,000 cp (at a temperature of between 20 and 20 DEG C); the sustained release auxiliary materials are selected from EVAc, Polifeprosan, PLA, PLGA, sebacic acid copolymer, albumin glue and gelatin, etc.; the sustained release microsphere can also be made into a sustained release implantation agent. The sustained release implantation agent and sustained release injection can be partly placed or injected into a bacteria focus so as to slowly release medicine over local bacteria focus for 5 to more than 30 days, thereby obviously reducing whole-length toxicity while effectively obtaining and maintaining the effective drug concentration of local focus. The sustained release preparation has remarkable and unique therapeutic effects in curing infections caused by staphylococcus, streptococcus, peptostreptococcus, propionibacterium acnes, enterobacter, tubercle bacillus, gonococcus or meningococcus, etc., and local focuses in particular such as chronic osteomyelitis, severe bedsore, intractable skin ulcer, diabetic foot, femoral head necrosis and various abscesses.
Owner:SHANDONG LANJIN PHARMA +1

Sustained-release injection containing biopalina

The invention relates to a slow-released injection comprising ribostamycin, which comprises a slow-released microsphere and a dissolvent; the slow-released microsphere comprises a slow-release adjuvant and the aminoglycoside antibiotic; the dissolvent is the special dissolvent which comprises a suspending agent such as sodium carboxymethylcellulose, etc., and the viscosity of which is 100cp-3000cp (at 20 DEG C-30 DEC C); the slow-release adjuvant can be selected from EVAc, polifeprosan, PLA, PLGA, sebacic acid copolymer, albumen glue and gelatin, etc.; the slow-released microsphere also can be made into a slow-released implant and an ointment. The slow-released implant and the slow-released injection can be partially placed or injected in a bacterial focus to release locally and slowly for more than 5-30 days, thereby obviously reducing the toxicity of the entire body while getting and maintaining a valid medicine density in the local focus effectively. The slow-released injection comprising the ribostamycin of the invention has obvious special treatment effect for focus of local infection such as chronic osteomyelitis, severe bedsore, refractory skin ulcer, diabetic foot, osteonecrosis of femoral head and various abscesses, etc., caused by staphylococcus, streptococcus, peptostreptococcus, propionibacterium acnes, enterobacter, tubercle bacillus, gonococcus and meningococcus, etc.
Owner:JINAN SHUAIHUA PHARMA TECH

Method for diagnosing Streptococcus, Enterococcus and Peptostreptococcus genera infections

The invention concerns a method to determine if an individual is infected by a bacterium selected from the group consisting Streptococcus, Enterococcus and Peptostreptococcus genera comprising: (i) detection of antibodies directed against at least one protein of sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8, in a biological sample of the individual, and (ii) deducing therefrom that the individual is infected by a bacterium selected from the group consisting of Streptococcus, Enterococcus and Peptostreptococcus genera. The invention further concerns the kit for diagnosing of such an infection.
Owner:DIAXONHIT

Sustained-release agent containing carbenicillin and use thereof

A sustained release preparation containing carbenicillin consists of sustained release microsphere and dissolvant, wherein the sustained release microsphere contains sustained release auxiliary materials and penicillins antibiotic; the dissolvant is special dissolvant containing suspending agents such as sodium carboxymethyl cellulose, and the viscosity of the dissolvant is 100 to 3,000 cp (at a temperature of between 20 and 20 DEG C); the sustained release auxiliary materials are selected from EVAc, Polifeprosan, PLA, PLGA, sebacic acid copolymer, albumin glue and gelatin, etc.; the sustained release microsphere can also be made into a sustained release implantation agent. The sustained release implantation agent and sustained release injection can be partly placed or injected into a bacteria focus so as to slowly release medicine over local bacteria focus for 5 to more than 30 days, thereby obviously reducing whole-length toxicity while effectively obtaining and maintaining the effective drug concentration of local focus. The sustained release preparation has remarkable and unique therapeutic effects in curing infections caused by staphylococcus, streptococcus, peptostreptococcus, propionibacterium acnes, enterobacter, tubercle bacillus, gonococcus or meningococcus, etc., and local focuses in particular such as chronic osteomyelitis, severe bedsore, intractable skin ulcer, diabetic foot, femoral head necrosis and various abscesses.
Owner:SHANDONG LANJIN PHARMA +1

Aptamers that are specific for immunoglobulin-binding cell wall proteins

The invention relates to an aptamer that binds to protein A, G or L, protein A-, G- or L-containing substances, and also to protein A-, G- or L-containing microorganisms, in particular Staphylococcus aureus, Streptococcus or Peptostreptococcus, methods for detection and enrichment of protein A, G or L, protein A-, G- or L-containing substances or protein A-, G- or L-containing microorganisms in which the aptamer is used, and also a kit, a biosensor, a lateral flow assay device and a measuring instrument which contain such an aptamer and can be used in said methods.
Owner:UFZ UMWELTFORSCHUNGSZENT LEIPZIG HALLE

Sustained-release agent containing ampicillin and use thereof

A sustained release preparation containing ampicillin consists of sustained release microsphere and dissolvant, wherein the sustained release microsphere contains sustained release auxiliary materials and penicillins antibiotic; the dissolvant is special dissolvant containing suspending agents such as sodium carboxymethyl cellulose, and the viscosity of the dissolvant is 100 to 3,000 cp (at a temperature of between 20 and 20 DEG C); the sustained release auxiliary materials are selected from EVAc, Polifeprosan, PLA, PLGA, sebacic acid copolymer, albumin glue and gelatin, etc.; the sustained release microsphere can also be made into a sustained release implantation agent. The sustained release implantation agent and sustained release injection can be partly placed or injected into a bacteria focus so as to slowly release medicine over local bacteria focus for 5 to more than 30 days, thereby obviously reducing whole-length toxicity while effectively obtaining and maintaining the effective drug concentration of local focus. The sustained release preparation has remarkable and unique therapeutic effects in curing infections caused by staphylococcus, streptococcus, peptostreptococcus, propionibacterium acnes, enterobacter, tubercle bacillus, gonococcus or meningococcus, etc., and local focuses in particular such as chronic osteomyelitis, severe bedsore, intractable skin ulcer, diabetic foot, femoral head necrosis and various abscesses.
Owner:SHANDONG LANJIN PHARMA +1

Method for Diagnosing Streptococcus, Enterococcus and Pepstostreptococcus Genera Infections

The invention concerns a method to determine if an individual is infected by a bacterium selected from the group consisting Streptococcus, Enterococcus and Peptostreptococcus genera comprising: (i) detection of antibodies directed against at least one protein of sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8, in a biological sample of the individual, and (ii) deducing therefrom that the individual is infected by a bacterium selected from the group consisting of Streptococcus, Enterococcus and Peptostreptococcus genera. The invention further concerns the kit for diagnosing of such an infection.
Owner:DIAXONHIT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products